Introduction
This was the first exploratory study to measure macular pigment levels and visual function in patients with mild to moderate Alzheimer’s disease (AD). Building on previous work identifying carotenoids in the brain and their potential influence on cognitive function, the study aimed to understand if macular pigment and vision-related quality of life were affected in this vulnerable population.
Why was the research undertaken?
Until this study, macular pigment had not been quantified in AD patients. We wanted to determine if there was a measurable difference in macular pigment and vision-related quality of life between AD patients and age-matched controls (people of the same age with no AD diagnosis) . We believed this could provide insight into the role of carotenoids in brain and eye health associated with AD.
How was the study conducted?
A safe, tailored protocol was developed to work with patients diagnosed with mild to moderate AD. We measured macular pigment levels, blood carotenoid concentrations, and vision function—especially contrast sensitivity—in AD patients and compared these to an age-matched control group free of AD but living in similar environments.
What were the results?
We found that AD patients had significantly lower macular pigment scores, and blood carotenoid levels compared to the control group. For the first time, a vision deficit was documented in AD patients, shown by reduced contrast sensitivity and lower vision-related quality of life scores.
What is the societal benefit?
This pioneering research highlighted a carotenoid deficiency and visual function impairment in people with Alzheimer’s disease compared to age-matched participants without the condition, revealing a previously unrecognized concern. The findings strongly support the need for clinical trials to investigate whether carotenoid supplementation could improve symptoms or slow disease progression, opening a promising new avenue for supportive therapies.
